John B Liao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3841225/publications.pdf

Version: 2024-02-01

		840776	1125743
16	385	11	13
papers	citations	h-index	g-index
16	16	16	763
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses. Clinical Cancer Research, 2021, 27, 6405-6412.	7.0	8
2	Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates., 2021, 9, e003122.		9
3	Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. Gynecologic Oncology, 2019, 153, 217-222.	1.4	38
4	Gynecologic cancers and solid organ transplantation. American Journal of Transplantation, 2019, 19, 1266-1277.	4.7	24
5	Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecologic Oncology, 2017, 144, 480-485.	1.4	12
6	Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. Gynecologic Oncology, 2017, 147, 291-295.	1.4	35
7	Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. Gynecologic Oncology Reports, 2017, 21, 78-80.	0.6	18
8	Surgical and oncologic outcomes after robotic radical hysterectomy as compared to open radical hysterectomy in the treatment of early cervical cancer. Journal of Gynecologic Oncology, 2017, 28, e82.	2.2	93
9	Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers. Journal of Gynecologic Oncology, 2016, 27, e47.	2.2	10
10	Immunotherapy for gynecologic cancers. Gynecologic Oncology, 2016, 142, 3-5.	1.4	11
11	Route of hysterectomy and surgical outcomes from a statewide gynecologic oncology population: is there a role for vaginal hysterectomy?. American Journal of Obstetrics and Gynecology, 2016, 214, 348.e1-348.e9.	1.3	15
12	Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer., 2015, 3, 16.		24
13	Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates. Gynecologic Oncology, 2015, 137, 430-435.	1.4	32
14	Therapeutic vaccines for ovarian cancer. Gynecologic Oncology, 2013, 130, 667-673.	1.4	16
15	SEX CORD-STROMAL AND GERM CELL TUMORS OF THE OVARY. , 2011, , 241-260.		0
16	Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecologic Oncology, 2011, 120, 464-469.	1.4	40